Modeling origin and natural evolution of low-grade gliomas

Similar documents
LOW GRADE ASTROCYTOMAS

The New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas

Neurosurgical Management of Brain Tumours. Nicholas Little Neurosurgeon RNSH

성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)

CNS pathology Third year medical students. Dr Heyam Awad 2018 Lecture 12: CNS tumours 2/3

Relationship of P53 Protein With Histopathology Degree of Intracranial Astrocytoma at Haji Adam Malik Hospital Medan

Mathematics Meets Oncology

Clinical Trials for Adult Brain Tumors - the Imaging Perspective

Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence

Chapter 1 Introduction

Understanding general brain tumor pathology, Part I: The basics. Craig Horbinski, M.D., Ph.D. Department of Pathology University of Kentucky

Silent Diffuse Low-Grade Glioma: Toward Screening and Preventive Treatment?

General: Brain tumors are lesions that have mass effect distorting the normal tissue and often result in increased intracranial pressure.

Mathematical modelling of spatio-temporal glioma evolution

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Cancer Treatment Using Multiple Chemotheraputic Agents Subject to Drug Resistance

21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

AMERICAN BRAIN TUMOR ASSOCIATION. Oligodendroglioma and Oligoastrocytoma

MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES

THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa

Computer Models of Brain Tumor Metastasis

Classification of Diffuse Gliomas: Progress, Pearls and Pitfalls. Rob Macaulay Neuropathologist, MCC October 21, 2017

WHY BIOPSY? Diagnosis and Research

ISSN: (Print) (Online) Journal homepage:

Astroblastoma: Radiologic-Pathologic Correlation and Distinction from Ependymoma

Predictive Biomarkers in GBM

A Model for Glioma Growth

Oligodendrogliomas & Oligoastrocytomas

Thierry M. Muanza, MSc, MD, FRCPC,, McGill University Segal Cancer Centre, Jewish General Hospital Montreal, QC, Canada

AMERICAN BRAIN TUMOR ASSOCIATION. Oligodendroglioma and Oligoastrocytoma

Corporate Medical Policy

Weather Cancer. Problem: Wanted: prediction But: difficult Why? Complex systems, i.e. many agents agents, feedback dynamics.

It s s Always Something!

Simulating the Tumor Growth with Cellular Automata Models

Radioterapia no Tratamento dos Gliomas de Baixo Grau

Cancer Stem Cells & Glioblastoma

5-hydroxymethylcytosine loss is associated with poor prognosis for

Pediatric Brain Tumors: Updates in Treatment and Care

General Identification. Name: 江 X X Age: 29 y/o Gender: Male Height:172cm, Weight: 65kg Date of admission:95/09/27

Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.

Review of Longitudinal MRI Analysis for Brain Tumors. Elsa Angelini 17 Nov. 2006

Five Most Common Problems in Surgical Neuropathology

MANAGEMENT N OF PRIMARY BRAIN TUMOURS IN THE ELDERLY

IDH1 R132H/ATRX Immunohistochemical validation

Glioblastoma Multiforme

Modeling Three-dimensional Invasive Solid Tumor Growth in Heterogeneous Microenvironment under Chemotherapy

Supplemental Figure 1. Intracranial transduction of a modified ptomo lentiviral vector in the mouse

Case Presentation: USCAP Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center

Laser Interstitial Thermal Therapy (LITT) in Neuro-Oncology. Tim Lucas, MD, PhD Neurosurgery

SUPPLEMENTARY INFORMATION

Imaging for suspected glioma

DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES

Clinical significance of genetic analysis in glioblastoma treatment

Institute of Oncology & Radiobiology. Havana, Cuba. INOR

Recent studies demonstrate that glioblastoma

Outstanding Questions from Webinar: Long-Term Survival Outcomes for LGG Patients, May 5 th, 2014

CNS SESSION 3/8/ th Multidisciplinary Management of Cancers: A Case based Approach

Glioblastoma. In this fact sheet: What is a glioblastoma?

The Glucose Ketone Index Calculator: A Simple Tool to Monitor Therapeutic. Efficacy for Metabolic Management of Brain Cancer

ΜΟΝΤΕΛΑ ΔΙAΧΥΣΗΣ ΚΑΡΚΙΝΙΚΩΝ ΟΓΚΩΝ ΕΓΚΕΦΑΛΟΥ

Anaplastic Pilocytic Astrocytoma: The fusion of good and bad

Zebrafish xenograft model of glioblastoma to identify regulatory pathways and agents

Corporate Medical Policy

Pet dog with tumor pioneered treatment

Tumor cut segmentation for Blemish Cells Detection in Human Brain Based on Cellular Automata

CRIPTO-1 A POSSIBLE NEW BIOMARKER IN GLIOBLASTOMA MULTIFORME PIA OLESEN, MD, PHD STUDENT

Gliomas in the 2016 WHO Classification of CNS Tumors

Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121

Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014

Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG

Tumors of the Central Nervous System

2017 Diagnostic Slide Session Case 3

Contemporary Management of Glioblastoma

CNS TUMORS. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

MOLECULAR DIAGNOSTICS OF GLIOMAS

HSV1716 Dose levels and Cohort size Dose level No of Patients HSV1716 Dosage 1* 3 to 6 1 ml of 1 x 10 5 infectious units HSV1716 per ml 2

Ion channels in the pathophysiology and therapeutics of brain tumors

Benjamin M. Ellingson, Ph.D.

Morphological features and genetic alterations

Clinical utility of precision medicine in oncology

Modeling Imatinib-Treated Chronic Myeloid Leukemia

Bevacizumab: A Controversial Agent Against High-Grade Gliomas

Innovative Multimodal Imaging Techniques in Brain Tumor Clinical Trials

PROCARBAZINE, lomustine, and vincristine (PCV) is

Image analysis in IHC overview, considerations and applications

Translating MRS into clinical benefit for children with brain tumours

Workshop on Biomedical Applications of High Energy Ion Beams

Clinical Management Protocol Chemotherapy [Glioblastoma Multiforme (CNS)] Protocol for Planning and Treatment

Precision medicine: How to exploit the growing knowledge on the evolving genomes of cells to improve cancer prevention and therapy.

Pathologic Analysis of CNS Surgical Specimens

How genetic & biochemical alterations in brain tumors contribute to epileptogenesis

Diffusion Restriction Precedes Contrast Enhancement in Glioblastoma Multiforme

Tumors of the Nervous System

SPECIAL SLIDE SEMINAR CASE 3

Use of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation.

MRI Applications in Radiation Oncology:

Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide

Regional Neuro-Oncology Service Information Evening

Brain tumors: tumor types

Transcription:

Modeling origin and natural evolution of low-grade gliomas Mathilde Badoual Paris Diderot University, IMNC lab 2nd HTE workshop: Mathematical & Computer Modeling to study tumors heterogeneity in its ecosystem, November 14th, 2018

Gliomas solid tumor only solid tumor+ isolated tumor cells isolated tumor cells only Grade I Grade III and IV Grade II Solid tumor tissue Isolated tumor cells Grade I: the grade I tumors may be curable by surgery Grade II diffuse astrocytomas or oligodendrogliomas: evolve 7-8 years in anaplastic tumors Grade III anaplastic gliomas: fatal evolution in 2 to 4 years. Grade IV glioblastoma multiforme: Average survival of 6 months to 2 years (based on feasible treatment). 2

Gliomas heterogeneity solid tumor only solid tumor+ isolated tumor cells isolated tumor cells only Grade I Grade III and IV Grade II Solid tumor tissue Isolated tumor cells Grade I: the grade I tumors may be curable by surgery Grade II diffuse astrocytomas or oligodendrogliomas: evolve 7-8 years in anaplastic tumors Grade III anaplastic gliomas: fatal evolution in 2 to 4 years. Grade IV glioblastoma multiforme: Average survival of 6 months to 2 years (based on feasible treatment). 3

Diffuse low-grade gliomas: recurrence Gliomas are rare tumors, but grade II (and more) gliomas cannot be cured systematic recurrence, even after treatments Glioma cells migrate normal surrounding tissue, causing recurrence of the tumor. Invasion plays a key role in the poor outcome of patients Shibahara, I et al (2015) Malignant clinical features of anaplastic gliomas without IDH mutation, Neuro Oncol., 17, 136-144. 4

A linear growth of the tumor radius Mandonnet E et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53, 524 528 5

Modeling tumor growth C( r, t) t Solution in 3D: = r(d( r, t)rc( r, t)) + ( r, t)c( r, t) if D and κ are uniforms and constants C(r, t) t = Dr 2 C(r, t)+ C(r, t) C(r,t) = N 0 (4πDt) 3 / 2 eκt e r 2 / 4 Dt large κ D detection threshold small κ D Assumption: diameter of the tumor on a MRI scan= iso cell density curve (C * ) r(t) = s 4Dt( t +ln( N 0 )) r(c C (4 Dt) 3/2,t!1)= p 4D t - <v> = 2 mm/yr - Linear evolution since r = 10 mm for the model rmin = 15 mm Cook J et al. (1995) Resection of gliomas and life expectancy, J Neurooncol. 24, 131 6

The natural history of low grade gliomas Onset Clinical diagnosis Anaplastic transformation Death Mean tumor diameter? Epilepsy No mass effect no contrast enhancement Mass effect Edema Contrast enhancement Necrosis anaplastic transformation = trigger of angiogenesis no symptoms Grade II 10 years symptoms Grade III and IV 1 year Time -Very invasive tumors but patients can live more than ten years after diagnosis Pallud J et al, (2008) Les gliomes infiltrants de bas grade, REG, Neurologies 11, 94-101 7

Oligodendrocyte precursor cells (OPCs) Cycling cells in the adult brain are mainly OPCs (NG2+ cells) Geha S et al., (2010), NG2+/Olig2+ cells are the major cycle-related cell population of the adult human normal brain, Brain Pathol., 20, 399-411 OPCs are the most widely distributed population of cycling cells in adult brain. In contrast, a small population of NSCs is found in the SVZ lining the lateral ventricles. Ilkanizadeh S et al, (2014), Glial Progenitors as Targets for Transformation in Glioma, Adv Cancer Res., 121, 1 65. 8

OPCs at the origin of gliomas? Mutated OPCs trigger gliomas in mouse. Zong H et al, (2012) The cellular origin for malignant glioma and prospects for clinical advancement, Expert Rev Mol Diagn., 12, 383-94 OPCs (Oligodendrocyte Precursor cells) are strongly suspected to be the cell of origin of some gliomas. 9

OPCs dynamics in vivo OPCs organize in a grid-like manner, with individual cells occupying almost non-overlapping domain Xu G et al, (2014), Spatial organization of NG2 glial cells and astrocytes in rat hippocampal CA1 region, Hippocampus, 24, 383-95 10

OPCs maintain a constant density in vivo death differentiation proliferation Hughes EG et al, (2013), Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain, Nat Neurosci., 16, 668-76. 11

Modeling OPCs dynamics 100μm Model: a cellular automaton without lattice (continuous space) A cell can: 1. proliferate ( proliferation rule) 2. migrate ( migration rule) Rules 3. and disappear (differentiate or die) (differentiation rule) 12

The formation of a glioma: different scenarios - - - Apparition of an immortal cell. Apparition of a cell that has lost its contact inhibition. Apparition of a highly proliferative cell. The daughter cells have the same proliferative properties than the mother cells. 13

The formation of a glioma: different scenarios First scenario: Apparition of an immortal cell 3200 Normal Cell density in a 1mm 3 volume Tumor 60 Proliferative cell density 2800 # cell/mm 3 Y-Title 2400 2000 # cell/mm 3 /day Y-Title 40 20 1600 400 900 500 1000 X-Title Time (days) 0 0 400 900 500 1000 X-Title Time (days) 14

The formation of a glioma: different scenarios First scenario: Apparition of an immortal cell # cell/mm 3 Y-Title 3200 2800 2400 2000 Normal Cell density in a 1mm 3 volume Tumor # cell/mm 3 /day Y-Title 60 40 20 Proliferative cell density The tumor cell proliferation goes to zero! Not compatible with experimental data 1600 400 900 500 1000 X-Title Time (days) 0 0 400 900 500 1000 X-Title Time (days) 15

The formation of a glioma: different scenarios Second scenario: Apparition of a cell without contact inhibition Cell density in a 1mm 3 volume Proliferative cell density 10000 Normal Tumor 500 400 # cell/mm 3 6000 2000 0 100 0 150 100 200 100 0 150 200 100 Time (days) # cell/mm 3 /day 300 200 100 Time (days) 16

The formation of a glioma: different scenarios Second scenario: Apparition of a cell without contact inhibition 10000 Normal Cell density in a 1mm 3 volume Tumor Very high cell and proliferation cell density high-grade glioma 500 Proliferative cell density 400 # cell/mm 3 6000 2000 0 100 0 150 100 200 100 0 150 200 100 Time (days) # cell/mm 3 /day 300 200 100 Time (days) 17

High-grade vs low-grade glioma H & E MIB-1 (immunostaining of proliferative cells) High grade Low grade Singh SK et al (2004), Identification of human brain tumour initiating cells, Nature, 432, 396-401. 18

Low-grade glioma # cell/mm 2 1400 1200 1000 800 800 600 400 400 200 0 0 # MIB-1 positive cells/mm 2 Normal Tumor Normal Tumor 15 10 10 5 0 5 0 H&E staining of a tumor tissue MIB1 immuno staining 19

The formation of a glioma: different scenarios Third scenario: Apparition of a highly proliferative cell Cell density in a 1mm 3 volume Proliferative cell density 2200 Normal Tumor 60 # cell/mm 3 2000 # cell/mm 3 /day 40 20 1800 1800 0 150 0 350 200 550 400 600 750 150 0 350 200 550 400 600 750 Time (days) Time (days) 20

The formation of a glioma: different scenarios Third scenario: Apparition of a highly proliferative cell Higher cell and proliferation cell density inside the tumor but not too high (a new equilibrium) low-grade glioma Cell density in a 1mm 3 volume Proliferative cell density 2200 Normal Tumor 60 # cell/mm 3 2000 # cell/mm 3 /day 40 20 1800 1800 0 150 0 350 200 550 400 600 750 150 0 350 200 550 400 600 750 Time (days) Time (days) 21

A highly proliferative cell at the origin of low-grade glioma A very proliferative cell in red Normal OPCs are in blue 22

Modeling the formation of a glioma 2000 2000 # cell/mm 3 Y-Title 1000 1000 Tumor cells are yellow to red (cell clock increasing) Normal OPCs are in blue to green (cell clock increasing) 0 0 200 400 600 X-Title Distance to the center (µm) Red curves: tumor cells; blue curves: normal cells Dufour A et al, (2018), Modeling the dynamics of oligodendrocyte precursor cells and the genesis of gliomas, PLoS Comput Biol., 14, e1005977. 23

Modeling the formation of a glioma 800 800 700 Mean radius (µm) 600 500 400 400 300 200 200 100 00 50 150 250 0 100 200 300 Time (days) With reasonable parameters, v 1 mm/yr 24

Modeling the formation of a glioma 800 800 700 Mean radius (µm) 600 500 400 400 300 200 200 100 00 50 150 250 0 100 200 300 Time (days) With reasonable parameters, v 1 mm/yr consistent with clinical data Mandonnet E et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol, 53, 524 528 25

First step of formation of a glioma OPC: oligodendrocyte precursor cell. The appearance of a highly proliferative OPC among normal OPCs leads to the formation of a glioma-like tumor: - invasive - slow linear increase of the radius, compatible with clinical data first step of heterogeneity: mixture and competition between normal and cancer cells Dufour A et al, (2018), Modeling the dynamics of oligodendrocyte precursor cells and the genesis of gliomas, PLoS Comput Biol., 14, e1005977. 26

Increasing heterogeneity Onset Clinical diagnosis Anaplastic transformation Death Mean tumor diameter Epilepsy No mass effect no contrast enhancement Mass effect Edema Contrast enhancement Necrosis anaplastic transformation = trigger of angiogenesis no symptoms Grade II 10 years symptoms Grade III and IV 1 year Time -Very invasive tumors but patients can live more than ten years after diagnosis Pallud J et al, (2008) Les gliomes infiltrants de bas grade, REG, Neurologies, 11, 94-101 27

Quantification of edema Tumor tissue: normal cells + tumor cells + edema + ECM +. -16-6 05 16 outside the tumor 16 P1 P4 P3 P2 P1 0 inside the tumor -6-16 (mm) P3 P4 =0.92(1.01 10 2 (R e G e )) 28 x : area fraction of edema

Edema/border of the tumor Edema fraction 100 80 60 40 20 inside the tumor oedema outside the tumor Patient number Patient number 10 8 6 4 2 1 2 3 4 5 6 7 8 9 0 20 10 0 10 20 30 dx (mm) 0 0 20 40 60 80 Edema fraction Edema fraction at x=0 Gerin C, et al (2013) Quantitative characterization of the imaging limits of diffuse low-grade oligodendrogliomas, Neuro-Oncology, 15, 1379. 29

A model with edema Equation for the cell density evolution: t = Dr2 + (1 ) Equation for the edema fraction evolution: ρ: tumor cell density ξ: edema fraction κ: proliferation D: diffusion λ: edema production μ: edema clearance t = (1 ) µ At the center, when ρ=1, reaches its maximum value that verifies: 1 e = e µ 30

Low-grade gliomas and radiotherapy Delay between the end of the radiotherapy and the regrowth of the tumor: Why? 31

Fit of clinical data clinical data model Badoual M, et al (2014) An oedema-based model for diffuse low-grade gliomas: application to clinical cases under radiotherapy, Cell Prolif, 47, 369 32

Conclusion When the tumor grows the heterogeneity increases. In low-grade gliomas, the heterogeneity is still low: easier for modeling. Two models, with increased heterogeneity, corresponding to different stages of evolution of a glioma. Next step: study of the apparition of heterogeneity between tumor cells (hypoxia) 33

Acknowledgments IMNC laboratory, Orsay, France Emilie Gontran, PhD student Aloys Dufour, undergraduate student Basile Grammaticos Christophe Deroulers Collaborators: Sainte-Anne hospital, Paris Johan Pallud, neurosurgeon Pascale Varlet, pathologist Catherine Oppenheimer, radiologist 34

Thank you for your attention! 35